Compare EML & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EML | STTK |
|---|---|---|
| Founded | 1858 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.2M | 119.0M |
| IPO Year | N/A | 2020 |
| Metric | EML | STTK |
|---|---|---|
| Price | $19.90 | $3.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 10.5K | ★ 328.1K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $258,121,226.00 | $1,000,000.00 |
| Revenue This Year | $1.56 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | $19.53 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.49 | $0.69 |
| 52 Week High | $30.72 | $3.38 |
| Indicator | EML | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 49.47 | 68.57 |
| Support Level | $19.73 | $1.93 |
| Resistance Level | $20.86 | $3.30 |
| Average True Range (ATR) | 0.65 | 0.24 |
| MACD | 0.19 | 0.06 |
| Stochastic Oscillator | 53.66 | 77.24 |
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.